IP Library › Granted Patent US 12,404,523
Granted Patent B2
US 12,404,523 · App. 17/427,010 · Granted Sep 2, 2025

Adeno-associated virus delivery of CLN3 polynucleotide

Inventors: Kathrin Meyer (Columbus, OH); Brian K. Kaspar (Columbus, OH); Kevin Foust (Columbus, OH)
Assignees: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL; OHIO STATE INNOVATION FOUNDATION
C12N15/86A61P3/00A61P25/00C07K14/47C12N7/00C12N2750/14143C12N2750/14171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,523
App. No.
17/427,010
Granted
Sep 2, 2025
Kind
B2
Abstract

The present disclosure relates to recombinant adeno-associated virus (rAAV) delivery of a ceroid lipofuscinosis neuronal 3 (CLN3) polynucleotide. The disclosure provides rAAV and methods of using the rAAV for CLN3 gene therapy of the neuronal ceroid lipofuscinosis or CLN3-Batten Disease.

Claims (42)

1. A nucleic acid molecule comprising at least 90% sequence similarity to the nucleic acid sequence of SEQ ID NO: 4.

2. The nucleic acid molecule of claim 1 , wherein the AAV inverted terminal repeats are AAV2 inverted terminal repeats.

3. A self-complementary recombinant adeno-associated virus 9 (scAAV9) comprising a nucleic acid molecule of claim 1 .

4. The scAAV9 of claim 3 , wherein the scAAV9 comprises a single-stranded genome.

5. An rAAV9 particle comprising a nucleic acid molecule of claim 1 .

6. The rAAV particle of claim 5 , wherein the rAAV particle comprises a single-stranded genome.

7. A method of treating CLN3-Batten Disease in a subject comprising administering to the subject a composition comprising a therapeutically effective amount of the rAAV9 particle of claim 5 .

8. The method of claim 7 , wherein the composition is administered via a route selected from the group consisting of intrathecal, intracerebroventricular, intraparenchymal, intravenous, and a combination thereof.

9. The method of claim 7 , wherein the composition is administered intrathecally.

10. The method of claim 7 , wherein the composition is administered intracerebroventricularly.

11. The method of claim 7 , wherein the composition is administered intravenously.

12. The method of claim 7 , wherein 1×10 12 to 1×10 15 vg of the rAAV9 viral particle is administered.

13. The method of claim 7 , wherein 6×10 13 to 1.2×10 14 of the rAAV9 viral particle is administered.

14. The method of claim 7 , further comprising a step of measuring one or more symptoms of CLN3-Batten Disease, wherein the treatment reduces or slows one or more symptoms of CLN3-Batten Disease, wherein the symptom comprises:

(a) lysosomal accumulation of autofluorescent storage material,

(b) lysosomal accumulation of ATP Synthase Subunit C,

(c) glial activation (astrocytes and/or microglia) activation,

(d) astrocytosis,

(e) brain volume loss measured by magnetic resonance imaging (MRI),

(f) onset of seizures, or

(g) one or more symptom of the Unified Batten Disease Rating Scale (UBDRS),

wherein the symptom is as compared to the subject prior to administering the composition or to an untreated CLN3-Batten Disease patient.

15. The method of claim 7 , further comprising placing the subject in the Trendelenburq position after administering the rAAV9 viral particle.

16. A method of treating a CLN3 disease in a subject in need thereof comprising, delivering a composition comprising the rAAV9 viral particle of claim 5 to a brain or spinal cord of a subject in need thereof.

17. The method of claim 16 , wherein the composition is delivered by intrathecal injection, intracerebroventricular injection, intraparenchymal injection, intravenous injection, or a combination thereof.

18. The method of claim 17 , further comprising placing the subject in the Trendelenburq position after intrathecal injection of the composition.

19. The method of claim 16 , wherein the composition comprises a non-ionic low-osmolar contrast agent.

20. The method of claim 19 , wherein the non-ionic, low-osmolar contrast agent is selected from the group consisting of iobitridol, iohexol, iomeprol, iopamidol, iopentol, iopromide, ioversol, ioxilan, and combinations thereof.

21. The method of claim 16 , wherein delivering to the brain or spinal cord comprises delivery to a brain stem.

22. The method of claim 16 , wherein delivering to the brain or spinal cord comprises delivery to a cerebellum.

23. The method of claim 16 , wherein delivering to the brain or spinal cord comprises delivery to a) a visual cortex, b) a motor cortex, c) a nerve cell or glial cell or both, d) a neuron, a lower motor neuron, a microglial cell, an oligodendrocyte, an astrocyte, a Schwann cell, or a combination thereof.

24. The method of claim 16 further comprising a step of measuring one or more symptoms of CLN3-Batten Disease, wherein the treatment reduces or slows one or more symptoms of CLN3-Batten Disease, wherein the symptom comprises:

(a) lysosomal accumulation of autofluorescent storage material,

(b) lysosomal accumulation of ATP Synthase Subunit C,

(c) glial activation (astrocytes and/or microglia) activation,

(d) astrocytosis,

(e) brain volume loss as measured by magnetic resonance imaging (MRI),

(f) onset of seizures, and

(g) one or more symptom of the Unified Batten Disease Rating Scale (UBDRS),

wherein the symptom is as compared to the subject prior to delivering the composition or to an untreated CLN3-Batten Disease patient.

25. A composition comprising the nucleic acid molecule of claim 1 and a pharmaceutically acceptable excipient, carrier, or diluent.

26. The composition of claim 25 , wherein the excipient comprises a non-ionic low osmolar compound, a buffer, a polymer, a salt, or a combination thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2025
From: MEYER, KATHRIN; KASPAR, BRIAN K.
To: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
Reel/Frame 071410/0012 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2025
From: FOUST, KEVIN
To: OHIO STATE INNOVATION FOUNDATION
Reel/Frame 071410/0405 →
Continuity (2)
Provisional Application 62800911 · Feb 4, 2019
Related Publication 20220127641A1 · Apr 28, 2022
References Cited (74)
US 5173414A · Lebkowski et al. · 1992 [cited by applicant]
US 5658776A · Flotte et al. · 1997 [cited by applicant]
US 5786211A · Johnson · 1998 [cited by applicant]
US 5871982A · Wilson et al. · 1999 [cited by applicant]
US 6258595B1 · Gao et al. · 2001 [cited by applicant]
US 6566118B1 · Atkinson et al. · 2003 [cited by applicant]
US 9434928B2 · Mendell et al. · 2016 [cited by applicant]
US 10876134B2 · Kielian · 2020 [cited by examiner]
US 20050053922A1 · Schaffer et al. · 2005 [cited by applicant]
US 20090202490A1 · Schaffer et al. · 2009 [cited by applicant]
US 20200179467A1 · Kaspar · 2020 [cited by examiner]
WO 9513365A1 · 1995 [cited by applicant]
WO 9513392A1 · 1995 [cited by applicant]
WO 9617947A1 · 1996 [cited by applicant]
WO 9706243A1 · 1997 [cited by applicant]
WO 9708298A1 · 1997 [cited by applicant]
WO 9709441A2 · 1997 [cited by applicant]
WO 9721825A1 · 1997 [cited by applicant]
WO 9809657A2 · 1998 [cited by applicant]
WO 9911764A2 · 1999 [cited by applicant]
WO 2014022582A1 · 2014 [cited by applicant]
WO WO2016100575A1 · 2016 [cited by examiner]
WO 2018094251A1 · 2018 [cited by applicant]
McCormack, P.L. “Iobitridol. A Review of Its Use as a Contrast Medium in Diagnostic Imaging.” Clinical Drug Investigation, vol. 33 (2013), pp. 155-166 (Year: 2013). [cited by examiner]
Castle, M.J. et al. “Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion.” Science Advances, vol. 4 (2018), p. 2aau9859 (Year: 2018). [cited by examiner]
PDF of Sequence listings from PCT-US15-66206 (downloaded from Espace.net/Global Dossier . (Year: 2016). [cited by examiner]
PDF of NM_000086.2- [cited by examiner]
Bosch et al., Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3), J. Neurosci., 36(37):9669-9682 (2016). [cited by applicant]
Cain et al., Gene Therapy Corrects Brain and Behavioral Pathologies in CLN6-Batten Disease, Mol. Ther., 27(10):1836-1847 (2019). [cited by applicant]
Carter, Adeno-associated virus vectors, Current Opinions in Biotechnology, 3(5):533-539 (1992). [cited by applicant]
Choudhury et al., In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy, Mol. Ther., 24(7):1247-1257 (2016). [cited by applicant]
Clark et al., A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors, Gene. Therapy, 3(12):1124-1132 (1996). [cited by applicant]
Clark et al., Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses, Hum. Gene. Ther., 10(6):1031-1039 (1999). [cited by applicant]
Cotman et al., Cln3(Deltaex7/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth, Hum. Mol. Genet., 11(22):2709-2721 (2002). [cited by applicant]
Cotman et al., The juvenile Batten disease protein, CLN3, and its role in regulating anterograde and retrograde post-Golgi trafficking, Clin. Lipidol., 7(1):79-91 (2012). [cited by applicant]
De et al., High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses, Mol. Th… [cited by applicant]
Gao et al., Clades of Adeno-associated Viruses Are Widely Disseminated in Human Tissues, J. Virol., 78:6381-6388 (2004). [cited by applicant]
Garg et al., Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome, J. Neurosci. 33:13612-13620 (2013). [cited by applicant]
Giles et al., Deamidation of Amino Acids on the Surface of Adeno-Associated Virus Capsids Leads to Charge Heterogeneity and Altered Vector Function, Molecular Therapy, 26(12):2848-2862 (2018). [cited by applicant]
Hermonat et al., Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells, Proc. Natl. Acad. Sci. U.S.A., 81(20):6466-6470 (1984). [cited by applicant]
International Application No. PCT/US20/16542, International Preliminary Report on Patentability, mailed Aug. 19, 2021. [cited by applicant]
International Application No. PCT/US20/16542, International Search Report and Written Opinion, mailed May 27, 2020. [cited by applicant]
Kitzmüller et al., A function retained by the common mutant CLN3 protein is responsible for the late onset of juvenile neuronal ceroid lipofuscinosis, Human Molecular Genetics, 17(2):303-312 (2008). [cited by applicant]
Laughlin et al., Cloning of infectious adeno-associated virus genomes in bacterial plasmids, Gene., 23(1):65-73 (1983). [cited by applicant]
Lebkowski et al., 1988 Mol. Cell. Biol., 7:349 (1988). [cited by applicant]
Lerner et al., Isolation of a Novel Gene Underlying Batten Disease, CLN3, Cell. 82(6):949-57 (1995). [cited by applicant]
Marshall et al., A clinical rating scale for Batten disease: reliable and relevant for clinical trials, Neurology, 65(2):275-279 (2005). [cited by applicant]
Marsic et al., Vector Design Tour de Force: Integrating Combinatorial and Rational Approaches to Derive Novel Adeno-associated Virus Variants, Molecular Therapy, 22(11):1900-1909 (2014). [cited by applicant]
McCarty et al., Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis, Gene. Therapy, 8(16):1248-1254 (2001). [cited by applicant]
McLaughlin et al., Adeno-associated virus general transduction vectors: analysis of proviral structures, J. Virol., 62(6):1963-73 (1988). [cited by applicant]
Mole et al., Genetics of the neuronal ceroid lipofuscinoses (Batten disease), Biochim Biophys Acta—Mol Basis Dis., 1852(10):2237-2241 (2015). [cited by applicant]
Mole et al., New mutations in the neuronal ceroid lipofuscinosis genes, Eur. J. Paediatr. Neurol., 5:7-10 (2001). [cited by applicant]
Morgan et al., A murine model of variant late infantile ceroid lipofuscinosis recapitulates behavioral and pathological phenotypes of human disease, PLoS One, 8(11):e78694 (2013). [cited by applicant]
Mori et al., Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein, Virology, 330(2):375-383 (2004). [cited by applicant]
Munroe et al., Spectrum of mutations in the Batten disease gene, CLN3, Am. J. Hum. Genet., 61(2):310-316 (1997). [cited by applicant]
Muzyczka, Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells, Current Topics in Microbiology and Immunology, 158:97-129 (1992). [cited by applicant]
Osorio et al., Neurodevelopmental delay in the Cln3Deltaex7/8 mouse model for Batten disease, Genes. Brain Behav., 8(3):337-345 (2009). [cited by applicant]
Palmer et al., Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease), Am. J. Med. Genet., 42(4):561-567 (1992). [cited by applicant]
Paul et al., Increased Viral Titer Through Concentration of Viral Harvests from Retroviral Packaging Lines, Human Gene Therapy, 4(5):609-615 (1993). [cited by applicant]
Perrin et al., An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system, Vaccine, 13(13):1244-1250 (1995). [cited by applicant]
Pontikis et al., Thalamocortical neuron loss and localized astrocytosis in the Cln3Deltaex7/8 knock-in mouse model of Batten disease, Neurobiol. Dis., 20(3):823-836 (2005). [cited by applicant]
Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, (1989). [cited by applicant]
Samulski et al., Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells, Proc. Natl. Acad. Sci. U.S.A., 79(6):2077-2081 (1982). [cited by applicant]
Samulski et al., Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression, J. Virol., 63(9):3822-3828 (1989). [cited by applicant]
Schenpp et al., Highly purified recombinant adeno-associated virus vectors. Preparation and quantitation, Methods Mol. Med., 69:427-443 (2002). [cited by applicant]
Seehafer et al., Immunosuppression alters disease severity in juvenile Batten disease mice, J. Neuroimmunol., 230(1-2):169-172 (2011). [cited by applicant]
Seehafer et al., You say lipofuscin, we say ceroid: defining autofluorescent storage material, Neurobiol. Aging., 27:576-588 (2006). [cited by applicant]
Seigel et al., Retinal pathology and function in a Cln3 knockout mouse model of juvenile Neuronal Ceroid Lipofuscinosis (batten disease), Mol Cell Neurosci., 19(4):515-27 (2002). [cited by applicant]
Senapathy et al., Molecular cloning of adeno-associated virus variant genomes and generation of infectious virus by recombination in mammalian cells, J. Biol. Chem., 259:4661-4666 (1984). [cited by applicant]
Sondhi et al., Partial Correction of the CNS Lysosomal Storage Defect in a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis by Neonatal CNS Administration of an Adeno-Associated Virus Serotype rh.10 Vector Express… [cited by applicant]
Srivastava et al., Nucleotide sequence and organization of the adeno-associated virus 2 genome, J. Virol., 45(2):555-564 (1983). [cited by applicant]
Tratschin et al., A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase, Mol. Cell. Biol., 4(10):2072-20… [cited by applicant]
Tratschin et al., Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells, Mol. Cell. Biol., 5(11):3251-3260 (1985). [cited by applicant]
GenBank Accession No. AAC05337, CLN3 [ [cited by applicant]